Clinical Trials Logo
  1. Home
  2. Metastatic Gastric Cancer
  3. NCT06250036

Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC) — ZODIAC  

Metastatic Gastric Cancer Clinical Trial

Official title:
A Randomised Phase II Study of Zimberelimab Anti-PD1 immunOtherapy +/- Domvanalimab Anti-TIGIT Immunotherapy in Resectable Mismatch Repair Deficient Gastric and Gastro-oesophageal Junctional AdenoCarcinoma

Clinical Trial Summary

A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma (AC)

Clinical Trial Description

Primary objective The primary objective of the trial is to evaluate the efficacy of zimberelimab +/- domvanalimab as preoperative treatment in improving the pathological complete response (pCR) rate as compared to standard FLOT chemotherapy in resectable dMMR/MSI-H gastric/GOJ AC and to identify the most promising experimental arm. Secondary objectives - To assess the safety and tolerability of zimberelimab+/- domvanalimab in this disease setting - To further assess the efficacy of zimberelimab+/- domvanalimab in terms of radiological response rate, R0 resection rate, progression free survival (PFS) and overall survival (OS) - To evaluate surgical outcomes following treatment with zimberelimab +/- domvanalimab Translational analyses on tissue and blood biomarkers aimed at identifying those who derive the most benefit from this immunotherapy combination, and those who are non/poor responders. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06250036
Study type Interventional
Source Royal Marsden NHS Foundation Trust
Contact Project Manager
Phone 02086613279
Email ZODIAC@rmh.nhs.uk
Status Not yet recruiting
Phase Phase 2
Start date April 1, 2024
Completion date September 1, 2031
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04618809 - Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer N/A
Recruiting NCT02668380 - An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer N/A
Completed NCT03121807 - Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer N/A
Recruiting NCT04358354 - Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer Phase 3
Completed NCT01099527 - A Trial of RAD001/Capecitabine in Refractory Gastric Cancer Phase 1/Phase 2
Completed NCT00253370 - Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT02002195 - Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Recruiting NCT06008925 - Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer Phase 1/Phase 2
Recruiting NCT05714124 - Liver Embolization Approaches for Tumor Management
Recruiting NCT02855788 - Metronomic Chemotherapy in Advanced Gastric Cancer Phase 2
Recruiting NCT03154983 - The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer Phase 2
Not yet recruiting NCT04263870 - Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Phase 2
Active, not recruiting NCT01359397 - Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT04739202 - Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) Phase 2
Completed NCT03409848 - Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma Phase 2
Recruiting NCT05859477 - Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer Phase 2
Recruiting NCT05955833 - 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study Phase 1
Terminated NCT01528501 - Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) Phase 2
Completed NCT03751761 - GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study Phase 1/Phase 2
Recruiting NCT05024812 - Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Phase 1/Phase 2